Several lines of evidence ranging from in vitro and in vivo studies in animals to humans have proved TRPV1 to be a potential target in nociceptors for the treatment of pathological pain, ranging from inflammation to neuropathies. This evidence concerns the gene TRPV1 and neuropathy.